Learn more

AVENTIS PHARMA INC

Overview
  • Total Patents
    2,543
  • GoodIP Patent Rank
    211,918
About

AVENTIS PHARMA INC has a total of 2,543 patent applications. Its first patent ever was published in 1990. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are BIOVITRUM AB, ICAGEN INC and BAYER PHARMACEUTICALS CORP.

Patent filings per year

Chart showing AVENTIS PHARMA INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Spada Alfred P 81
#2 Merrill Jean 79
#3 Chandross Karen 76
#4 Bordeau Kenneth J 76
#5 Eishingdrelo Haifeng 76
#6 August Paul 74
#7 Chiang Yulin 66
#8 Natesan Sridaran 65
#9 Grueneberg Dorre 61
#10 Jurcak John G 60

Latest patents

Publication Filing date Title
ZA201309537B Pharmaceutical composition comprising fexofedine
TN2013000470A1 Pharmaceutical composition comprising fexofenadine
TW201311239A Pharmaceutical composition comprising fexofenadine
EP2709600A1 Pharmaceutical composition comprising fexofenadine
AU2012202514A1 Method for measuring resistance or sensitivity to docetaxel
AU2012200293A1 Method for measuring resistance or sensitivity to docetaxel
AU2012200306A1 Method for measuring resistance or sensitivity to docetaxel
AU2012200307A1 Method for measuring resistance or sensitivity to docetaxel
AU2012200305A1 Method for measuring resistance or sensitivity to docetaxel
CA2793324A1 A substituted pyrimidine as a prostaglandin d2 receptor antagonist
CA2793223A1 Substituted pyrimidines as prostaglandin d2 receptor antagonists
AU2008202190A1 Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
AU2008201798A1 Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands
AU2007216625A1 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
USH2246H Method for analyzing continuous glucose monitoring data
CN101321523A Use of a CB1 antagonist for treating side effects and negative symptoms of schizophrenia
US2008139556A1 N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof
US2007142417A1 Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
US2007129401A1 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CN101287714A Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist